News

Treatment with a dry powder inhaler (DPI) formulation of ensifentrine led to clinically meaningful and sustained improvement in lung function in people with moderate to severe chronic obstructive pulmonary disease (COPD), according to early data from a Phase 2 trial. Ensifentrine (RPL554) is an inhibitor of the phosphodiesterase…

Differences in DNA may explain lung health and the risk of chronic obstructive pulmonary disease (COPD) in both smokers and non-smokers and could help in the future development of preventive and therapeutic strategies against COPD, a large-scale study reports. The study, “New genetic signals for lung function highlight pathways and…

Hoping to increase awareness of an often-debilitating and misdiagnosed lung condition called nontuberculous mycobacterial (NTM) lung disease, the COPD Foundation is hosting a Facebook discussion on Feb. 28  in recognition of Rare Disease Day. The 1 p.m. EST event is titled “Constant Cough, Fatigue & Shortness of…

The lungs are one of the most essential yin organs of our lives, and they are extremely fragile. They filter, they distill, they respond, and they act accordingly. They provide the container for the breath — the alchemy that is life. Chronic obstructive pulmonary…

Patients with chronic obstructive pulmonary disease (COPD) are unaware of their increased lung cancer risk compared with the general population — attributing their chest symptoms to factors other than potential cancer signs, according to a study. The researchers recommended campaigns to raise awareness about this risk since early lung cancer detection…

Orion and Propeller Health have established a collaboration to offer a custom sensor and mobile app to digitally monitor medication use with Easyhaler — a metered-dose dry powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Developed by Orion and available across Europe, Easyhaler is a line of…

Statins, commonly used to lower blood cholesterol levels, can help chronic obstructive pulmonary disease (COPD) patients by preventing or treating COPD-related comorbidities, and by improving patients’ lung function and exercise capacity, according to a meta-analysis study of existing research data. Results from the meta-analysis, titled “Effectiveness of long-term using…

Nuvaira, a medical device company, announced it has secured $79 million to support the AIRFLOW-3 clinical trial to assess the company’s new targeted lung denervation (TLD) system, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). COPD includes a group of diseases characterized by chronic airway obstruction…

The first generic version of the inhalation treatment Advair Diskus (fluticasone/salmeterol powder) was recently approved by the U.S. Food and Drug Administration for chronic obstructive pulmonary disease (COPD) and asthma patients. According to a press release from developer Mylan, the therapy, called Wixela Inhub (fluticasone propionate and salmeterol inhalation powder),…

People with chronic obstructive pulmonary disease (COPD) have an increased risk of severe illness, hospitalization, and death if they become infected with the influenza virus, according to a Canadian study. Researchers emphasize that getting a flu vaccine can significantly reduce these risks. The study, published in the journal…